• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Downgraded, Again

anonymous

Guest
Well Patterson stock downgraded, yet again, from $34 to $28. That is the sweet spot for the current regime of idiots in the C Suite and those running dental. Who would have ever thought that vet would be consistently pulling dentals ass out of the the fire but here we are. At the C Suite level we have two accountants, neither of which know anything about the dental business running the show. They think everything can be fixed by cutting expenses which means dollars to help us grow sales. So not marketing funds means no sales growth. At the dental leadership level, well we have the three blind mice at the top...